Technology

搜索文档
Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
GlobeNewswire News Room· 2025-07-10 19:35
ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) NEW YORK and NORTH CHICAGO, Ill., July 10, 2025 (GLOBE NEWSWIRE) -- IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), and AbbVie (NYSE: ABBV) today announced an exclusive licensing agreement for IGI’s lead investigational asset, ISB 2001, developed using IGI’s proprietary BEAT® protein platform, for oncology and autoimmune diseases. “Multispeci ...
AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
Prnewswire· 2025-07-10 19:30
ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM)NORTH CHICAGO, Ill. and NEW YORK, July 10, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), today announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT® protein platform, for oncology and autoimmune diseases."Multispecifics ...
BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient
Globenewswire· 2025-07-10 19:30
[IMAGES BELOW] Sustained complete resolution of temporal lobe brain metastasis and continued orbital tumor reduction after >18 months of treatment“Eye bulging” metastatic breast cancer patient had failed 8 prior regimens, including antibody-drug conjugate (ADC) therapyPatient remains on BriaCell’s Phase 2 study with 29 treatment cycles completed PHILADELPHIA and VANCOUVER, British Columbia, July 10, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or t ...
中国科学院院士潘建伟:我国在量子通信领域已处于国际引领地位【附量子信息产业分析】
前瞻网· 2025-07-10 19:22
(图片来源:摄图网) 在量子计算领域,中国同样交出了一份亮眼的成绩单。 量子通信,是利用量子力学原理对信息进行编码、传输和处理的一种新型通信方式,以其高度的安全性和传 输效率,成为当今信息通信领域的前沿技术,是量子信息学的核心分支。具有不可克隆、不可分割和不可预 测的特性,能够从根本上保证信息传输的绝对安全。 尽管2023年中国量子通信市场规模仅约6亿元,但随着国防、信息安全需求的不断增长,其战略价值已获全 球认可。量子通信正从实验室走向产业化,成为守护国家信息安全的"国之重器"。 7月6日,中国科协副主席、中国科学技术大学常务副校长、中国科学院院士潘建伟在第二十七届中国科协年 会主论坛上表示,我国在量子通信领域已处于国际引领地位。他指出,我国在量子通信领域取得了一系列重 要成果,包括成功发射"墨子号"量子科学实验卫星,建成"京沪干线"地面光纤网络和国家广域量子保密通信 骨干网,并实现了与奥地利、南非的洲际量子密钥分发。此外,我国科学家还在合肥完成首批严格的器件无 关量子密钥分发实验,为信息安全提供了坚实保障。 潘建伟还提到,我国在量子计算领域处于国际第一方阵,在量子精密测量领域部分方向处于国际领先或先进 水 ...
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
ZACKS· 2025-07-10 19:22
The SPDR S&P Biotech ETF (XBI) made its debut on 01/31/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.What Are Smart Beta ETFs?The ETF industry has traditionally been dominated by products based on market capitalization weighted indexes that are designed to represent the market or a particular segment of the market.Investors who believe in market efficiency should consider market cap indexes, as they replicate market returns in a lo ...
Garrett Motion to Hold Second Quarter 2025 Financial Results Conference Call on Thursday July 24, 2025
Globenewswire· 2025-07-10 19:00
PLYMOUTH, Mich. and ROLLE, Switzerland, July 10, 2025 (GLOBE NEWSWIRE) -- Garrett Motion Inc. (Nasdaq: GTX), a leading provider of differentiated automotive technology, today announced that it plans to release its second quarter financial results on Thursday, July 24, 2025, prior to the opening of the market trading in the United States. Garrett will host a conference call that same day at 8:30 am EDT / 2:30 pm CET. To participate in the conference call, please dial +1-877-883-0383 (U.S.) or +1-412-902-6506 ...
Passage Bio Announces 1-for-20 Reverse Stock Split
Globenewswire· 2025-07-10 19:00
PHILADELPHIA, July 10, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (“Passage Bio” or the “Company”) (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that its Board of Directors (“Board”) has approved a reverse stock split of the company’s outstanding shares of common stock at a ratio of 1-for-20. The reverse stock split will become effective at 12:01 a.m. Eastern time on July 14, 2025. Passage Bio’s common s ...
InMode to Report Second Quarter 2025 Financial Results and Hold Conference Call on July 30, Expects Q2 Revenue Between $95.4M-$95.5M, Decreases Full Year 2025 Revenue Guidance to be Between $365M-$375M
Prnewswire· 2025-07-10 19:00
Conference call to be held on Wednesday, July 30, 2025, at 8:30 a.m. Eastern TimeYOKNEAM, Israel, July 10, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the second quarter 2025 before the Nasdaq market opens on Wednesday, July 30, 2025.InMode is currently finalizing its financial results for the second quarter of 2025. While complete financial information and operating data a ...
14亿天价薪酬!华人AI大佬被挖走
中国基金报· 2025-07-10 18:48
【导读】曾领导苹果公司基础模型团队的Ruoming Pang从苹果跳槽至Meta,扎克伯格不惜重金为Meta的新部门招兵买马 中国基金报记者 泰勒 大家好,关注一下AI圈的大消息。 Meta挖角苹果工程师,薪酬包超2亿美元 Meta(原Facebook)为其"超级智能"团队的新成员提供了异常高额的薪酬,包括为一名前苹果杰出工程师开出的超过2亿美元(约人民币 14亿元)的薪酬包。 据悉,Meta聘用了曾负责苹果AI模型团队的Ruoming Pang,提供的是数亿美元规模、跨越数年的薪酬方案。苹果并未尝试匹配该报价, 因为除了首席执行官蒂姆·库克外,这远超苹果公司任何高管的薪酬水平。 这些薪酬方案与Meta"超级智能"新团队的其他重要招募保持一致。据称,该团队的目标是打造能够与人类一样好甚至更好的AI系统。目前 团队成员还包括前GitHub首席执行官Nat Friedman,以及AI初创企业创始人Daniel Gross。Meta还通过收购Scale AI公司49%的股份 (估值143亿美元),任命其联合创始人Alexandr Wang为Meta的首席AI官。 从纯数字角度来看,这支超级智能团队的薪酬在全球所有企 ...
奇点国峰:拟一家以兴趣电商AI赋能服务为核心业务的AI技术公司
快讯· 2025-07-10 18:47
收购意向 - 奇点国峰于2025年7月10日签署不具法律约束力的投资意向书 拟收购一家以兴趣电商AI赋能服务为核心业务的AI技术公司100%股权 [1] - 目标公司估值范围为3 5亿至5亿港元 最终对价将基于独立评估机构估值报告及尽职调查结果确定 [1] - 潜在交易对价拟以发行香港联交所上市新股作为支付方式 [1] 交易进程 - 公司将在投资意向书签署后两个月内对目标公司完成尽职审查 [1] - 公司计划在签署后两个月内与卖方就正式收购协议展开进一步谈判 [1]